Intellectual property, licensing and business development professionals will gather around the world to celebrate World IP Day and the importance of IP to the global economy. Participating LES (USA & Canada) local chapters and LESI societies will host events open to anyone, including non members. Events may include networking receptions and/or educational programs.
Online Registration Deadline Closed: Onsite Registration Available
Please note: Checks and Cash Only
DATE & TIME
Tuesday, April 26, 2011
6:00 PM - 9:00 PM
IP Management: This is how we do it! How do you do it?
(Differences & Similarities in Deal Structures for Pharma and Telecommunications)
Two key industry sectors of the Licensing Executives Society (Life Sciences and High Technology) are widely represented in NJ by pharmaceutical and telecommunication companies. Each type of company has its own concerns and approaches to managing Intellectual Property, while both aim to protect its assets and guide licensing deals that will contribute to company growth.
In the telecommunications industry, standards setting and interoperability have been key factors in the growth and adoption of new technology. As a result there has been extensive cross-licensing among industry participants. Recently the open source movement has been pushing for free exchange of IP rights. We will explore how this and changes with an open innovation model have been impacting licensing deals in the high tech sector.
In contrast the pharma /biotech industry relies heavily on the non-accessibility of IP rights, i.e., the exclusive dominion of commercialization of a product by single/dual entities until patent expiration – the exact antithesis of open source. Cross-licensing is reserved for special situations, while the majority of deal making in pharma/biotech involves standard licensing, co-development/co-commercialization arrangements, option deals and M&A with variations thereof.
Despite differing views on IP management, both industries are thriving. This meeting will feature a panel discussion by our distinguished guests from Merck and Alcatel-Lucent to point out the differences and similarities in securing IP for commercializing products and ensuring the Licensor gets adequate return for its contribution. Join us for this exciting program and exceptional networking event to celebrate World IP Day, Tuesday, April 26th.
Donald P. Dinella
Chief Technology Counsel & VP, IP Global Operations, Intellectual Property & Standards
VP & Group Managing Counsel, Intellectual Property Group
Merck & Co., Inc.
Christine T. Fischette, PhD
Griffin Securities, Inc.
Basking Ridge Country Club
185 Madisonville Road
Basking Ridge, NJ 07920
LES Member: $30
Online Registration Deadline Extended: Monday, April 25, 12 PM
LES Member: $40
Checks and Cash Only
(Sorry, no credit cards)
- networking cocktail reception with open bar
- hors d'oeuvres
- carving station
- light buffet
- coffee and dessert
No refunds after April 22
LES Photo Release Policy
Registrant grants permission to LES (USA & Canada) to use registrant's image or likeness for any and all promotional purposes.
Program & Location
LES New Jersey Chapter Chair
Thanks to our sponsor, Merck & Co., Inc., we are offering a special advance registration fee
Donald P. Dinella - Alcatel-Lucent
Mr. Dinella is currently the Chief Technology Counsel & VP, IP Global Operations for Alcatel-Lucent’s Intellectual Property & Standards organization having worldwide responsibility for the licensing and business development, patent creation and patent portfolio management, IP law services and IP strategy functions. In this capacity he manages a diverse group of IP professionals consisting of IP lawyers, business and technical personnel. He began his career with AT&T as a manufacturing engineer thereafter holding positions in the Intellectual Property Division as a Licensing Manager and Law Division as a patent attorney. In 1996, he joined Lucent Technologies where he handled a wide variety of IP legal assignments including IP transactional matters and patent prosecution. In 2006, with the merger between Alcatel and Lucent Technologies, he was assigned to his current position. Don holds a Bachelor’s degree in Mechanical Engineering from Villanova University (1985), an M.S. in Computer Science from the New Jersey Institute of Technology (1989), an M.S. in Computer Integrated Manufacturing from Brigham Young University (1989) and a J.D. from Seton Hall University School of Law (1993). Mr. Dinella is a registered Patent Attorney with the USPTO and a LES Member.
William Krovatin - Merck & Co., Inc.
Mr. Krovatin is VP & Group Managing Counsel, Intellectual Property Group, Merck & Co., Inc. He has been with Merck for 18 years in the legal department where he has held positions as a patent lawyer handling worldwide patent litigation for various products, as a transaction attorney supporting the licensing and business development group at Merck, and back to the IP group coordinating and supervising the patent support for the licensing and business development group. In his current position of Group Managing Counsel he oversees approximately 40 attorneys including five Managing Counsels who report directly to him. He has a Bachelor of Science degree in molecular biology from the Massachusetts Institute of Technology (1980) and a JD from Rutgers Law School-Newark (1987).
Christine T. Fischette, PhD – Griffin Securities, Inc.
Dr. Fischette is Senior Advisor at Griffin Securities, Inc., NY, NY, and President & CEO of her own business development consulting firm, CTF, LLC. She was President of the biotech firm, Enzo Therapeutics, Inc. from 2008-2010 and prior to that spent 25+ years in Big Pharma with responsibilities in multiple areas of drug development, commercialization and business development. She functioned as Executive Director and Head of Negotiation, Global Business Development and Licensing for various therapeutic Business Franchise Boards at Novartis Pharmaceuticals from 1999-2007, where she identified, negotiated and executed a number of deals involving various deal structures, including acquisitions, with US, European, Japanese and Indian companies, large and small. She held various positions of increasing responsibility at Pfizer, Inc., New York City, directing preclinical/clinical development, IND’s/NDA’s, medical marketing, marketing and business development from 1987-1999. During that time she directed the entire drug development process and subsequent marketing effort for an anti-diabetes therapy as head of Pfizer’s US commercial arm for diabetes. Net sales of the franchise eventually reached approximately $350m. Prior to Pfizer she conducted research as Senior Scientist at Hoffmann-La Roche, Inc. and as a Post-Doctoral Fellow/Research Associate at Rockefeller University, NYC. Dr. Fischette holds a Ph.D. in Physiology from the University of Medicine & Dentistry of New Jersey. She has authored over 50 publications in peer-reviewed publications, including Science. She is a member of the Healthcare Businesswomen’s Association and the Licensing Executives Society.